trial · primary record
Survodutide
Metabolic Dysfunction Associated Steatohepatitis
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 1590 |
| Primary completion | 2029-06-05 |
| Primary endpoint | Time to first occurrence of any component of the composite clinical endpoint (at EoS) consisting of: all-cause mortality, liver transplant, hepatic decompensation events, worsening of MELD score to ≥15 and progression to CSPH |
| Registry ID | NCT06632457 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:43:49.831Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06632457
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Survodutide · compound